Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Transseptal access for MViV replacement cuts mortality

Key clinical point: Transseptal catheter access for mitral valve-in-valve replacement is tied to lower mortality, compared with transapical access, and is an independent predictor of lower mortality at 1 year.

Major finding: All-cause mortality at 1 year – the primary efficacy endpoint – was 15.8% with a transseptal approach versus 21.7% with a transapical approach (hazard ratio, 0.67; 95% confidence interval, 0.47-0.97; P = .03).

Study details: This was a review of more than 1,500 mitral valve-in-valve cases.

Disclosures: The work was funded by Edward Lifesciences, which did the statistical analysis. The study lead disclosed receiving research funding from the company.

Citation:

Guerrero M. TCT 2019.